Bekendtgørelse om euforiserende stoffer – 61 nye stoffer tilføjet
30. marts 2026
Bekendtgørelse om euforiserende stoffer – 61 nye stoffer tilføjet
I Indenrigs- og Sundhedsministeriets bekendtgørelse nr. 405 af 26. marts 2026 om euforiserende stoffer er der fra den 29. marts 2026 optaget følgende nye stoffer på bilag 1.
Oplysningerne er primært relevante for virksomheder med tilladelse til at håndtere euforiserende stoffer.
Som det fremgår, optages der følgende stoffer på liste B:
- 1. 5,3-AB-CHMFUPPYCA (N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-5-(4-fluorophenyl)-1H-pyrazol-3-carboxamid)
- 12. ADB-B-5Br-INACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-5-bromo-1-butyl-1H-indazol-3-carboxamid)
- 16. ADB-D-5Br-INACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-5-bromo-1-decyl-1H-indazol-3-carboxamid)
- 17. 3,5-ADB-4en-PFUPPYCA (N-(1-carbamoyl-2,2-dimethyl-propyl)-5-(4-fluorophenyl)-2-pent-4-enyl-pyrazol-3-carboxamid)
- 18. ADB-4en-PINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(pent-4-en-1-yl)-1H-indazol-3-carboxamid)
- 19. ADB-FUBIACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indol-3-acetamid)
- 21. ADB-HEXINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-hexyl-1H-indazol-3-carboxamid)
- 23. ADB-PINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazol-3-carboxamid)
- 25. ADMB-INACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1H-indazol-3-carboxamid)
- 24. ADMB-5en-HEXINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(hex-5en-1-yl)-1H-indazol-3-carboxamid)
- 26. ADMB-3TMS-PRINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(3-(trimethylsilyl)propyl)-1H-indazol-3-carboxamid)
- 27. A-FUBIACA (N-(1-adamantyl)-2-[1-[(4-fluorophenyl)methyl]indol-3-yl]acetamid)
- 29. AKB-57 (1-adamantyl 1-pentylindazol-3-carboxylat)
- 46. AMB-CHMICA (methyl 2-((1-(cyclohexylmethyl)-1H-indol-3-yl)formamido)-3-methylbutanoat)
- 47. AMB-4en-PICA (methyl 3-methyl-2-[1-(pent-4-en-1-yl)-1H-indol-3-carboxamido]butanoat)
- 51. AM-6527 5-fluoropentyl derivat (1-(5-fluoropentyl)-N-(naphthalen-1-yl)-1H-indol-3-carboxamid)
- 57. A-PBITMO (adamantan-1-yl(3-pentyl-2-thioxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)methanon)
- 59. A-PONASA (N-(adamantan-1-yl)-4-(pentyloxy)naphthalen-1-sulfonamid)
- 60. BB-22 (8-quinolinyl 1-(cyclohexylmethyl)-1H-indol-3-carboxylat)
- 90. CH-BINACA (1-butyl-N-cyclohexyl-1H-indazol-3-carboxamid)
- 91. CH-FUBBMPDORA (N-{5-bromo-1-[(4-fluorophenyl)methyl]-4-methyl-2-oxo-1,2-dihydropyridin-3-yl}cyclohexancarboxamid)
- 92. CH-FUBIACA (N-cyclohexyl-2-(1-(4-fluorobenzyl)-1H-indol-3-yl)acetamid)
- 95. CHM-MDA-19 (N-[(Z)-[1-(cyclohexylmethyl)-2-oxo-indolin-3-ylidene]amino]benzamid)
- 98. 5Cl-MDMB-PINACA (methyl 2-(1-(5-chloropentyl)-1H-indazol-3-carboxamido)-3,3-dimethylbutanoat)
- 114. CUMYL-CBMICA (1-(Cyclobutylmethyl)-N-(2-phenylpropan-2-yl)-1H-indol-3-carboxamid)
- 116. CUMYL-EINACA (1-Ethyl-N-(2-phenylpropan-2-yl)-1H-indazol-3-carboxamid)
- 119. CUMYL-FUBINACA (1-[(4-fluorophenyl)methyl]-N-(2-phenylpropan-2-yl)-1H-indazol-3-carboxamid)
- 120. CUMYL-INACA ((N-(2-Phenylpropan-2-yl)-1H-indazol-3-carboxamid)
- 121. CUMYL-NBMINACA (1-(bicyclo[2.2.1]heptan-2-ylmethyl)-N-(2-phenylpropan-2-yl)-1H-indazol-3-carboxamid)
- 123. CUMYL-PINACA (1-pentyl-N-(2-phenylpropan-2-yl)-1H-indazol-3-carboxamid)
- 124. CUMYL-PMINACA (1-pentyl-N-(2-phenylpropan-2-yl)-4,5,6,7-tetrahydro-1H-4,7-methanoindazol-3-carboxamid)
- 125. CUMYL-3TMS-PRINACA (N-(2-phenylpropan-2-yl)-1-(3-(trimethylsilyl)propyl)-1H-indazol-3-carboxamid)
- 160. EDMB-4en-PINACA (ethyl 3,3-dimethyl-2-{[1-(pent-4-en-1-yl)-1H-indazol-3-carbonyl]amino}butanoat)
- 163. 4en-PDMB-4en-PINACA (pent-4-en-1-yl 3,3-dimethyl-2-(1-(pent-4-en-1-yl)-1H-indazol-3-carboxamido)-butanoat)
- 182. 4F-ABINACA (N-(adamantan-1-yl)-1-(4-fluorobutyl)-1H-indazol-3-carboxamid)
- 184. 5F-ADB-PINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazol-3-carboxamid)
- 185. 4F-ADMB-BINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobutyl)-1H-indazol-3-carboxamid)
- 191. 5F-EDMB-PINACA (ethyl-2-[1-(5-fluoropentyl)-1H-indazol-3-carboxamido]-3,3-dimethylbutanoat)
- 207. 5F-MDMB-P7AICA (methyl 2-{[1-(5-fluoropentyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]formamido}-3,3-dimethylbutanoat)
- 209. 4F-MDMB-PINACA (methyl 2-[1-(4-fluoropentyl)-1H-indazol-3-carboxamido]-3,3-dimethylbutanoat)
- 213. 5F-SDB-005 (naphthalen-1-yl 1-(5-fluoropentyl)-1H-indazol-3-carboxylat)
- 214. FUB-NPB-22 (8-quinolyl 1-[(4-fluorophenyl)methyl]indazol-3-carboxylat)
- 226. HU-331 (3-hydroxy-2-(6-isopropenyl-3-methyl-cyclohex-2-en-1-yl)-5-pentyl-1,4-benzoquinon)
- 257. JWH-018 indazol analog (naphthalen-1-yl(1-pentyl-1H-indazol-3-yl)methanon)
- 271. MADMB-4en-PINACA (N-(3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl)-1-(pent-4-en-1-yl)-1H-indazol-3-carboxamid)
- 274. MDA-19 4en-pentyl analog (N-[(Z)-(2-oxo-1-pent-4-enyl-indolin-3-yliden)amino]benzamid)
- 276. MDA-19 pentyl analog (N-[(Z)-(2-oxo-1-pentyl-indolin-3-ylidene)amino]benzamid)
- 278. MDMB-BINACA (methyl 2-(1-butyl-1H-indazol-3-carboxamido)-3,3-dimethylbutanoat)
- 279. MDMB-5Br-INACA (methyl 2-(5-Bromo-1H-indazol-3-carboxamido)-3,3-dimethylbutanoat)
- 280. MDMB-7Br-INACA (methyl 2-(7-bromo-1H-indazol-3-carboxamido)-3,3-dimethylbutanoat)
- 283. MDMB-CHMINACA (methyl 2-(1-(cyclohexylmethyl)-1H-indazol-3-carboxamido)-3,3-dimethylbutanoat)
- 284. MDMB-5en-HEXINACA (methyl 2-(1-(hex-5-en-1-yl)-1H-indazol-3-carboxamido)-3,3-dimethylbutanoat)
- 285. MDMB-4en-P-5Br-INACA (methyl 2-{[5-bromo-1-(pent-4-en-1-yl)-1H-indazol-3-carbonyl]amino}-3,3-dimethylbutanoat)
- 287. MDMB-FUBINACA (methyl 2-(1-(4-fluorobenzyl)-1H-indazol-3-carboxamido)-3,3-dimethylbutanoat)
- 288. MDMB-INACA (methyl 2-(1H-indazole-3-carboxamido)-3,3 -dimethylbutanoat)
- 289. MDMB-PINACA (methyl 3,3-dimethyl-2-(1-pentyl-1H-indazol-3-carboxamido)butanoat)
- 335. MMB-PINACA (methyl 3-methyl-2-[(1-pentyl-1H-indazol-3-carbonyl)amino]butanoat)
- 343. MPhP-2201 (methyl 2‐(1‐(5‐fluoropentyl)‐1H‐indol-3-carboxamido)‐3‐phenylpropanoat)
- 360. NMDMSB (1-naphthyl 4-methyl-3-(dimethylsulfamoyl)-benzoat)
- 420. SDB-005 (naphthalen-1-yl 1-pentyl-1H-indazol-3-carboxylat)
- 447. URB-597 (3'-carbamoylbiphenyl-3-yl cyclohexylcarbamat)
Efter 29 marts 2026 må disse stoffer kun håndteres med tilladelse fra Lægemiddelstyrelsen. Import og eksport af disse stoffer må desuden kun foretages, såfremt Lægemiddelstyrelsen i hvert enkelt tilfælde har udstedt et certifikat.
De 61 stoffer må dermed udelukkende anvendes i medicinsk eller videnskabeligt øjemed.
Yderligere oplysninger kan fås ved henvendelse via e-post: Send en mail